143 related articles for article (PubMed ID: 16138827)
1. Functional analysis of p53 tumor suppressor in yeast.
Smardová J; Smarda J; Koptíková J
Differentiation; 2005 Jul; 73(6):261-77. PubMed ID: 16138827
[TBL] [Abstract][Full Text] [Related]
2. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
3. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124.
Smardová J; Pavlová S; Svitáková M; Grochová D; Ravcuková B
Oncol Rep; 2005 Oct; 14(4):901-7. PubMed ID: 16142349
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
[TBL] [Abstract][Full Text] [Related]
5. Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.
Wu XM; Fu JG; Ge WZ; Zhu JY; Wang JY; Zhang W; Qian W; Huo KK
J Zhejiang Univ Sci B; 2007 Feb; 8(2):81-7. PubMed ID: 17266182
[TBL] [Abstract][Full Text] [Related]
6. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
7. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
8. FASAY: a simple functional assay in yeast for identification of p53 mutation in tumors.
Smardová J
Neoplasma; 1999; 46(2):80-8. PubMed ID: 10466430
[TBL] [Abstract][Full Text] [Related]
9. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
[TBL] [Abstract][Full Text] [Related]
10. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles.
Rand A; Glenn KS; Alvares CP; White MB; Thibodeau SM; Karnes WE
Cancer Lett; 1996 Jan; 98(2):183-91. PubMed ID: 8556707
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of transcript mutations due to transcriptional slippage in rat p53 tumor suppressor gene with the use of yeast functional assay].
Ba Y
Hokkaido Igaku Zasshi; 1999 May; 74(3):173-88. PubMed ID: 10422562
[TBL] [Abstract][Full Text] [Related]
12. Screening patients for heterozygous p53 mutations using a functional assay in yeast.
Ishioka C; Frebourg T; Yan YX; Vidal M; Friend SH; Schmidt S; Iggo R
Nat Genet; 1993 Oct; 5(2):124-9. PubMed ID: 8252037
[TBL] [Abstract][Full Text] [Related]
13. [Analyses of p53 mutations in breast cancers with a combined use of yeast functional assay and immunohistochemical staining].
Takahashi M
Hokkaido Igaku Zasshi; 1998 May; 73(3):275-86. PubMed ID: 9719952
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
15. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
16. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
[TBL] [Abstract][Full Text] [Related]
17. Improved detection of p53 point mutations by dideoxyfingerprinting (ddF).
Martincic D; Whitlock JA
Oncogene; 1996 Nov; 13(9):2039-44. PubMed ID: 8934553
[TBL] [Abstract][Full Text] [Related]
18. Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study.
Fouquet C; Antoine M; Tisserand P; Favis R; Wislez M; Commo F; Rabbe N; Carette MF; Milleron B; Barany F; Cadranel J; Zalcman G; Soussi T
Clin Cancer Res; 2004 May; 10(10):3479-89. PubMed ID: 15161705
[TBL] [Abstract][Full Text] [Related]
19. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
20. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]